Literature DB >> 3363220

Cyclosporine disposition in the hyperlipidemic rat model.

L J Brunner1, K Vadiei, D R Luke.   

Abstract

Since cyclosporine is heavily bound to plasma lipoproteins, its pharmacokinetic profile was evaluated in the Zucker hyperlipidemic rat model (N = 4) and compared to Zucker lean (N = 4) and Sprague-Dawley (N = 4) rat models. Following a single i.v. dose (5 mg/kg) of cyclosporine, serial blood samples, collected by tail bleed, were assayed for cyclosporine concentration by radioimmunoassay. Pharmacokinetic analysis was performed by standard non-compartmental methods. Half-lives between the three groups were not different. However, Zucker obese rats demonstrated a significantly smaller volume of distribution at steady-state (2.8 +/- 1.1 L/kg; p less than 0.01) versus the Zucker lean (5.4 +/- .9 L/kg) and Sprague-Dawley rats (5.6 +/- .7 L/kg). Likewise, the total body clearance was markedly reduced in the obese (0.24 +/- .09 L/h/kg; p less than 0.01) versus lean (0.51 +/- .04 L/h/kg) and Sprague-Dawley (0.52 +/- .06 L/h/kg) rat models. This data suggests the ability of lipids to significantly impair the intracellular transfer of cyclosporine and may impact on its clinical monitoring, efficacy and toxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3363220

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  6 in total

1.  Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function.

Authors:  Hamidreza Montazeri Aliabadi; Tara J Spencer; Parvin Mahdipoor; Afsaneh Lavasanifar; Dion R Brocks
Journal:  AAPS J       Date:  2006-10-27       Impact factor: 4.009

2.  Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats.

Authors:  Ellen Q Wang; Ho-Leung Fung
Journal:  AAPS PharmSci       Date:  2002

Review 3.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.

Authors:  Ric M Procyshyn; Kishor M Wasan; Allen E Thornton; Alasdair M Barr; Eric Y H Chen; Edith Pomarol-Clotet; Emmanuel Stip; Richard Williams; G William Macewan; C Laird Birmingham; William G Honer
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

5.  The cyclosporin-erythromycin interaction: impaired first pass metabolism in the pig.

Authors:  D J Freeman; D R Grant; S G Carruthers
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

6.  Liposomal formulations of cyclosporin A: influence of lipid type and dose on pharmacokinetics.

Authors:  A Fahr; M Holz; G Fricker
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.